Physician profile
Gordon M Thomas
NPI 1083665582
$2,509.87
in general payments reported to CMS, 2019-2025
21 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $23.37 · 2021: $97.72 · 2022: $217 · 2023: $482 · 2024: $886 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $563.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $277.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $257.53 | 2022-2025 | Rexulti |
| Abbvie INC. | $221.32 | 2021-2025 | Qulipta |
| Pfizer INC. | $196.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $177.63 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $163.66 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $127.72 | 2019-2023 | Veozah |
| Lundbeck LLC | $100.02 | 2022-2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $91.61 | 2024-2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.66 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $40.78 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $36.56 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $32.26 | 2019 | |
| Allergan, INC. | $28.87 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.41 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $26.61 | 2019-2024 | Camzyos |
| Abbott Laboratories | $20.95 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.80 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $16.59 | 2024 | Belbuca |
| Sanofi-Aventis U.S. LLC | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.